PetMeds Restates Financials, Eyes Omnichannel Growth & Telehealth

Ticker: PETS · Form: 10-K · Filed: 2025-10-14T00:00:00.000Z

Sentiment: mixed

Topics: Pet Healthcare, E-commerce, Financial Restatement, Internal Controls, Telemedicine, Omnichannel Retail, Pet Medications

TL;DR

**PETS' restatement reveals internal control flaws, but strategic pivots into omnichannel and telehealth could be a lifeline in a competitive pet market.**

AI Summary

PetMed Express, Inc. (PETS) filed a comprehensive 10-K for the fiscal year ended March 31, 2025, which included restatements for fiscal years 2023 and 2024 due to income statement classification errors. The company misclassified vendor-funded promotional sales reimbursements as revenue instead of reductions to cost of sales or advertising expense, though this had no impact on net income. PETS reported attracting approximately 351,000 new customers in fiscal 2025, a decrease from 457,000 in fiscal 2024. The average order value slightly increased to approximately $97 in fiscal 2025 from $94 in fiscal 2024. The company acquired PetCareRx, Inc. in April 2023, expanding its product catalog beyond core pet prescriptions to include Rx and non-Rx food and supplies. PETS is evolving into an omnichannel business, launching its private label assortment on Amazon in early FY2026, and has partnered with Dutch Pet, Inc. in May 2025 to offer virtual veterinary care in 34 states.

Why It Matters

This restatement, while not impacting net income, highlights material weaknesses in PetMed Express's internal controls, which RSM US LLP issued an adverse opinion on. For investors, this raises concerns about financial reporting reliability and operational oversight, potentially impacting investor confidence and stock valuation. The strategic shift towards an omnichannel model and partnerships like Dutch Pet, Inc. are crucial for PETS to compete in the expanding $152 billion pet care market, especially given the reported muted pet household adoptions and pricing pressure in 2025. Employees and customers will see an expanded product range and enhanced services, but the company must effectively address its internal control issues to ensure long-term stability and growth against competitors.

Risk Assessment

Risk Level: high — The company explicitly states that RSM US LLP issued an adverse opinion on its internal control over financial reporting, indicating significant deficiencies. Furthermore, the need for restatement across multiple fiscal years (2023, 2024, and 2025 quarterly reports) due to income statement classification errors, despite no net income impact, points to a systemic issue in financial reporting processes. This level of control weakness presents a high risk for future financial accuracy and regulatory compliance.

Analyst Insight

Investors should exercise caution and closely monitor PETS' progress in remediating its material weaknesses in internal controls, as an adverse opinion from RSM US LLP is a significant red flag. While strategic initiatives like the Dutch Pet partnership and omnichannel expansion are positive, their success hinges on improved operational execution and financial transparency. Consider waiting for evidence of strengthened internal controls before making significant investment decisions.

Key Numbers

Key Players & Entities

FAQ

Why did PetMed Express restate its financial statements for fiscal years 2023 and 2024?

PetMed Express restated its financial statements due to income statement classification errors. The company incorrectly accounted for vendor-funded promotional sales reimbursements as revenue, which should have been recorded as a reduction to cost of sales or advertising expense, as determined in discussion with RSM US LLP.

What was the impact of the restatement on PetMed Express's net income?

The restatement had no impact on PetMed Express's net income or other financial statements, including the consolidated balance sheets, statements of cash flows, or statements of changes in shareholders' equity. The reclassification only affected individual line items on the statements of operations.

What is the significance of RSM US LLP's adverse opinion on PetMed Express's internal controls?

RSM US LLP's adverse opinion on PetMed Express's internal control over financial reporting signifies that there are material weaknesses in the company's internal controls. This indicates a high risk of misstatements in financial reporting and a lack of effective processes to ensure financial accuracy.

How many new customers did PetMed Express acquire in fiscal year 2025?

PetMed Express attracted approximately 351,000 new customers in fiscal year 2025. This represents a decrease from the approximately 457,000 new customers acquired in fiscal year 2024.

What was the average order value for PetMed Express in fiscal year 2025?

The average order value for PetMed Express in fiscal year 2025 was approximately $97. This was a slight increase compared to approximately $94 in fiscal year 2024.

What strategic initiatives is PetMed Express undertaking to expand its business?

PetMed Express is evolving from a digital-only model to an omnichannel business, launching its private label assortment on Amazon in early FY2026. The company also acquired PetCareRx, Inc. in April 2023 to expand its product catalog and partnered with Dutch Pet, Inc. in May 2025 to offer virtual veterinary care services.

What is the total addressable market for pet products and services in the U.S.?

According to the American Pet Products Association, pet spending in the United States increased by 3% to $152 billion in 2024. Veterinary care and prescription medications accounted for $39.8 billion, or 26% of that total.

How does PetMed Express ensure regulatory compliance for its pharmacies?

PetMed Express has made investments in its pharmacies to ensure regulatory compliance, including implementing a rigorous verification process from order to shipment. They employ licensed pharmacists and a 50-state licensed Pharmacist-in-Charge for each of their two pharmacy locations, and their pharmacies are accredited by NABP.Com and LegitScript.

What services does PetMed Express offer through its partnerships?

PetMed Express offers extended services through partnerships, including telehealth with Dutch Pet, Inc. and Vetster, pet insurance, and employee benefits programs through Pet Synergy Group. The Dutch partnership, announced in May 2025, provides virtual veterinary care in 34 states.

What are the key risks highlighted in the PetMed Express 10-K?

Key risks include material weaknesses in internal control over financial reporting, as evidenced by the adverse opinion from RSM US LLP and the need for financial restatements. Additionally, the company faces challenges from muted pet household adoptions and pricing pressure in the pet retail market, as noted in the April 2025 Cleveland Research Pet Retail and Animal Health Report.

Risk Factors

Industry Context

The U.S. pet spending market reached $152 billion in 2024, growing by 3%, indicating a robust and expanding industry. Veterinary care and prescriptions, a key segment for PETS, represent $39.8 billion (26%) of this total. The market is characterized by increasing demand for premium products, convenience, and integrated health solutions, including telehealth, driving innovation among players like PETS.

Regulatory Implications

As a pharmacy, PETS faces significant regulatory scrutiny regarding prescription drug sales, data privacy, and compounding. Changes in federal and state regulations, or increased enforcement, could necessitate costly operational adjustments and impact service offerings. Compliance with evolving pharmacy laws is critical for continued operation and growth.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Omnichannel
A retail strategy that integrates various channels (online, mobile, physical stores, etc.) to provide a seamless customer experience. (PETS is actively evolving into an omnichannel business, indicating a strategic shift to meet customers across multiple touchpoints.)
Vendor-funded promotional sales reimbursements
Payments received from vendors to offset costs associated with promoting their products, such as advertising or special displays. (These were previously misclassified as revenue, highlighting a past accounting error that required restatement, though it did not impact net income.)
Average Order Value (AOV)
The average amount of money a customer spends per order. (An increase in AOV suggests customers are spending more per transaction, which is a positive indicator of customer value and product mix.)
Virtual veterinary care
Healthcare services for pets provided remotely through telecommunications technology, such as video calls or online consultations. (PETS' partnership with Dutch Pet, Inc. to offer this service signifies an expansion into telehealth, a growing segment in the pet industry.)

Year-Over-Year Comparison

While specific comparative financial figures for FY2025 versus FY2024 are not detailed in this excerpt, the 10-K indicates restatements for FY2023 and FY2024 due to income statement classification errors, which did not impact net income. Key operational shifts include a decrease in new customer acquisition in FY2025 compared to FY2024, though average order value saw a slight increase. The company has also made significant strategic moves, such as the Dutch Pet partnership, which were not present in the prior year's filing.

Filing Stats: 4,379 words · 18 min read · ~15 pages · Grade level 14.7 · Accepted 2025-10-14 16:27:15

Key Financial Figures

Filing Documents

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 9 Item 1B. Unresolved Staff Comments 22 Item 1C. Cybersecurity 22 Item 2

Properties

Properties 24 Item 3.

Legal Proceedings

Legal Proceedings 24 Item 4. Mine Safety Disclosures 25 PART II 26 Item 5. Market for Registrant's Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities 26 Item 6. [Reserved] 28 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 40 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 84 Item 9A.

Controls and Procedures

Controls and Procedures 84 Item 9B. Other Information 87 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 89 PART III 90 Item 10. Directors, Executive Officers, and Corporate Governance 90 Item 11.

Executive Compensation

Executive Compensation 100 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 121 Item 13. Certain Relationships and Related Transactions, and Director Independence 123 Item 14. Principal Accountant Fees and Services 124 PART IV 125 Item 15. Exhibit and Financial Statement Schedules 125 Item 16. Form 10-K Summary 127

SIGNATURES

SIGNATURES 128 EXPLANATORY NOTE PetMed Express, Inc. ("we," "us," "our," or the " Company ") is filing this comprehensive annual report on Form 10-K for the fiscal years ended March 31, 2025, March 31, 2024, and March 31, 2023 (the "Comprehensive Form 10-K"). This Comprehensive Form 10-K contains our audited financial statements for the fiscal year ended March 31, 2025, as well as restatements of the following previously filed periods: (i) our audited consolidated financial statements as of and for the years ended March 31, 2024 and 2023 originally included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 (the "2024 10-K"); (ii) our unaudited condensed consolidated quarterly financial information included in our Quarterly Reports on Form 10-Q for the quarterly periods within the fiscal years ended March 31, 2024 and 2023 (collectively, the " Historical Quarterly Reports "); and (iii) our unaudited condensed consolidated financial statements in our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2024, September 30, 2024 , and December 31, 2024 (collectively, the "2025 Quarterly Reports" and together with the Historical Quarterly Reports and the 2024 10-K, the "Prior Reports" and all financial statements included in the Prior Reports, collectively the "Affected Financial Statements"). Background and Effects of the Restatement As previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on October 7, 2025, the Audit Committee of the Board of Directors, after discussions with management and the Company's independent registered public accounting firm, RSM US LLP ("RSM"), concluded that the Affected Financial Statements should no longer be relied upon. This conclusion resulted from income statement classification errors described below. As a result, any related press releases, investor presentations, shareholder communications, or other materials that desc

, Item 1A. Risk Factors;

Part I, Item 1A. Risk Factors;

, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations; and

Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations; and

, Item 9A. Controls and Procedures

Part II, Item 9A. Controls and Procedures. The Company has not filed, and does not intend to file, amendments to the previously filed Prior Reports. Accordingly, investors should rely only on the financial information and other disclosures regarding the Affected Financial Statements in this Comprehensive Form 10-K or in future filings with the SEC (as applicable), and not on any previously issued or filed reports, earnings releases or similar communications relating to these periods. See Note 1 and Note 18 to the consolidated financial statements, included in Part II, Item 8 of this Comprehensive Form 10-K, for additional information on the restatement and the related consolidated financial statement effects. See Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations for a discussion of the Completion of the Audit Committee Investigation. PART I CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION Certain information in this Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plan," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of this Annual Report

BUSINESS

ITEM 1. BUSINESS GENERAL PetMed Express, Inc. and subsidiaries, d/b/a PetMeds, and as parent company of PetCareRx, is a pioneer in pet healthcare, building a consumer-first digital platform in 1996 that transformed the way customers fulfill pet medications. Nearly thirty years later, as a leading nationwide direct-to-consumer pet health and wellness retailer, the Company markets and sells directly to consumers through its websites (Petmeds.com and PetCareRx.com), customer contact center (1-800-PetMeds), and mobile applications (iOS and Android). The Company provides access to top branded pharmaceuticals, generic medications, compounded prescription medications, pharmacy fulfillment, and personalized autoship capabilities. Our digital platform offers pet healthcare solutions for a broad range of chronic conditions, including those related to allergy, arthritis, anxiety, kidney, hyperthyroidism, and others for cat, dog, and horses. We also offer access to a range of non-prescription health and wellness products and Rx food, non-Rx food, and treats. PetMeds and PetCareRx receive the pet's prescription through our websites and connects to the customer's licensed veterinarian for approval. Through our content website, pethealthmd.com, consumers can access educational articles for any health-related questions regarding their pets. The Company offers consumers an attractive alternative for obtaining pet medications, foods, and supplies in terms of convenience, price, speed of delivery, and valued customer service. Through partnerships with 75,000 2 veterinarians and a loyal customer base who rely on our services, our in-house pharmacies and extended pet healthcare partnerships seek to offer unparalleled value and convenience to families at every stage of their pets' lives. We are deeply committed to the mission and purpose that has driven our business from the start. Since our founding, we have fulfilled orders for almost twenty-million pet parents in all 50 states

View on Read The Filing